Table II.
Demographics and baseline characteristics—subjects with family history of atopy (asthma, allergic dermatitis, or allergic rhinitis) or food allergies
| Palivizumab treated |
Palivizumab untreated |
Palivizumab untreated non-RSV hospitalized |
|
|---|---|---|---|
| Variable | (n = 90) | (n = 130) | (n = 79§) |
| Mean birth weight (kg) ± SD (range) | 1.36 ± 0.44 (0.6-3.2) | 1.65 ± 0.54‡ (0.6-3.8) | 1.58 ± 0.45† (0.6-2.7) |
| Mean gestational age (wk) ± SD (range) | 29.9 ± 2.08 (25-35) | 31.3 ± 2.44‡ (25-35) | 31.0 ± 2.26† (27-35) |
| Female sex (%) | 53.3 | 42.3 | 40.5 |
| White race (%) | 93.3 | 95.4 | 96.2 |
| Multiple birth (%) | 33.3 | 39.2 | 38.0 |
| Mean enrollment age (mo) ± SD (range) | 17.9 ± 8.11 (4-36) | 19.5 ± 9.76 (1-38) | 18.9 ± 10.92 (1-38) |
| Mean enrollment weight (kg) ± SD (range) | 10.19 ± 2.59 (3.8-19.3) | 10.12 ± 2.81 (2.6-16.6) | 9.77 ± 2.94 (3.1-16.6) |
| Breast-fed (%) | 71.1 | 68.5 | 68.4 |
| Mean number of siblings ± SD (range) | 1.0 ± 1.01 (0-5) | 1.3 ± 1.02∗ (0-5) | 1.1 ± 0.93 (0-4) |
| Siblings in day care (%) | 40.0 | 52.3 | 48.1 |
| Subject in day care (%) | 20.0 | 33.1∗ | 36.7∗ |
| Smokers in home (%) | 43.3 | 36.9 | 39.2 |
| Caregiver smokes (%) | 27.8 | 21.5 | 22.8 |
| Pets in home (%) | 33.3 | 33.8 | 31.6 |
| Wood-burning stove (%) | 13.3 | 13.8 | 15.2 |
| Family history of asthma (%) | 50.0 | 45.4 | 49.4 |
| Family history of atopic dermatitis %) | 16.7 | 19.2 | 16.5 |
| Family history of allergic rhinitis (%) | 56.7 | 54.6 | 54.4 |
| Family history of food allergies (%) | 14.4 | 16.2 | 17.7 |
| Family history of any atopy (%) | 94.4 | 90.8 | 88.6 |
| Family history of any atopy or food allergies (%) | 100 | 100 | 100 |
| RSV antibody (% <2log2) | 38.4 | 29.4 | 38.5 |
| IgE antibody (% <5 IU/ML) | 49.4 | 53.3 | 57.9 |
∗
P ≤ .050.
†
P ≤ .010.
‡
P ≤ .001 for comparison with palivizumab-treated group.
§
The 79 children were a subgroup of the 130 untreated subjects.